EPO-α/Fc Chimera, Human

该产品已下架。

Erythropoietin (EPO), a glycoprotein produced primarily by the kidney, is the principal factor that regulates erythropoiesis by stimulating the proliferation and differentiation of erythroid progenitor cells. The production of EPO by kidney cells is increased in response to hypoxia or anemia. Recombinant EPO has been approved for the treatment of anemia associated with chronic renal failure as well as for anemia of AZT treated AIDS patients.Erythropoietin/Fc Chimera is a long-acting version of EPO.

产品编号	Z02907
规格	定制报价

联系我们

产品简介

Species	Human
Purity	>98% by SDS-PAGE and HPLC analyses.
Endotoxin Level	Less than 0.2EU/ug of rHuEPO-Fc a as determined by LAL method.
Formulation	Lyophilized from a 0.2um filtered concentrated solution in PBS, pH 7.4.
Reconstitution	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at <-20℃. Further dilutions should be made in appropriate buffered solutions.

技术背景

Target Background

Erythropoietin (EPO), a glycoprotein produced primarily by the kidney, is the principal factor that regulates erythropoiesis by stimulating the proliferation and differentiation of erythroid progenitor cells. The production of EPO by kidney cells is increased in response to hypoxia or anemia. Recombinant EPO has been approved for the treatment of anemia associated with chronic renal failure as well as for anemia of AZT treated AIDS patients. Erythropoietin/Fc Chimera is a long-acting version of EPO.

Synonyms

EPO-Fc Human;